CTLA4 and melanoma: A combination of anti-PD1 and anti-CTLA4 blockade therapy with nivolumab and ipilimumab was found to have a higher ORR (57%) than monotherapy with ipilimumab (19%) and nivolumab (44%) in a phase 3 study in patients with untreated melanoma, suggesting increased efficacy in combination.